Novo Nordisk sues Eli Lilly over GLP-1 advertising claims
Statements (10)
- Bearish
Hundreds of consumers are suing GLP-1 drug makers over vision loss claims
- Bearish
Novo Nordisk lost its GLP-1 lead to Eli Lilly & Co.
- Neutral
Novo Nordisk is escalating a lawsuit against Eli Lilly over obesity treatment marketing
- Bearish
Eli Lilly is suing pharmacies and peptide vendors over sale of retatrutide
- Bearish
Novo Nordisk A/S filed a lawsuit in U.S. federal court against Eli Lilly and Company
- Bullish
Lilly and Novo Nordisk won an antitrust lawsuit over access to compounded GLP-1 drugs.
- Neutral
Eli Lilly and Novo Nordisk may see increased market confidence as they secure a legal victory in the GLP-1 antitrust dispute.
- Neutral
Novo Nordisk sued Eli Lilly over GLP-1 drug advertising claims.
- Neutral
Novo Nordisk sues Eli Lilly over weight-loss drug ads comparing their products.
- Neutral
Novo Nordisk is seeking a preliminary U.S. court injunction to block Eli Lilly's weight-loss drug advertisements